Progressive Degeneration of Human Mesencephalic Neuron-Derived Cells Triggered by Dopamine-Dependent Oxidative Stress Is Dependent on the Mixed-Lineage Kinase Pathway

Models of Parkinson's disease (PD) based on selective neuronal death have been used to study pathogenic mechanisms underlying nigral cell death and in some instances to develop symptomatic therapies. For validation of putative neuroprotectants, a model is desirable in which the events leading to neurodegeneration replicate those occurring in the disease. We developed a human in vitro model of PD based on the assumption that dysregulated cytoplasmic dopamine levels trigger cell loss in this disorder. Differentiated human mesencephalic neuron-derived cells were exposed to methamphetamine (METH) to promote cytoplasmic dopamine accumulation. In the presence of elevated iron concentrations, as observed in PD, increased cytosolic dopamine led to oxidative stress, c-Jun N-terminal kinase (JNK) pathway activation, neurite degeneration, and eventually apoptosis. We examined the role of the mixed-lineage kinases (MLKs) in this complex degenerative cascade by using the potent inhibitor 3,9-bis[(ethylthio)methyl]-K-252a (CEP1347). Inhibition of MLKs not only prevented FeCl2+/METH-induced JNK activation and apoptosis but also early events such as neurite degeneration and oxidative stress. This broad neuroprotective action of CEP1347 was associated with increased expression of an oxidative stress-response modulator, activating transcription factor 4. As a functional consequence, transcription of the cystine/glutamate and glycine transporters, cellular cystine uptake and intracellular levels of the redox buffer glutathione were augmented. In conclusion, this new human model of parkinsonian neurodegeneration has the potential to yield new insights into neurorestorative therapeutics and suggests that enhancement of cytoprotective mechanisms, in addition to blockade of apoptosis, may be essential for disease modulation.

[1]  F. Tietze Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. , 1969, Analytical biochemistry.

[2]  D. Graham Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[3]  G. Cohen,et al.  Coupling of Dopamine Oxidation (Monoamine Oxidase Activity) to Glutathione Oxidation Via the Generation of Hydrogen Peroxide in Rat Brain Homogenates , 1981, Journal of neurochemistry.

[4]  R. Guillery,et al.  Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain , 1982, Brain Research.

[5]  L. Seiden,et al.  Alpha-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes , 1983, Brain Research.

[6]  L. Seiden,et al.  Increased dopamine metabolism in the rat neostriatum after toxic doses of d-methylamphetamine , 1983, Neuropharmacology.

[7]  L. Seiden,et al.  Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers , 1984, Brain Research.

[8]  C. J. Schmidt,et al.  Role of dopamine in the neurotoxic effects of methamphetamine. , 1985, The Journal of pharmacology and experimental therapeutics.

[9]  Seiden Ls Methamphetamine: toxicity to dopaminergic neurons. , 1985 .

[10]  L. Seiden Methamphetamine: toxicity to dopaminergic neurons. , 1985, NIDA research monograph.

[11]  R. Carelli,et al.  Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. , 1985, Research communications in chemical pathology and pharmacology.

[12]  G. C. Wagner,et al.  Methamphetamine-induced neuronal damage: A possible role for free radicals , 1989, Neuropharmacology.

[13]  D. Sulzer,et al.  Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: A mechanism of action , 1990, Neuron.

[14]  K. Jellinger,et al.  Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.

[15]  N. Neff,et al.  K‐252a and Staurosporine Promote Choline Acetyltransferase Activity in Rat Spinal Cord Cultures , 1993, Journal of neurochemistry.

[16]  K. Jellinger,et al.  Neuromelanin and Nigrostriatal Dopamine Neuron Degeneration , 1993, Journal of Neurochemistry.

[17]  C. Epstein,et al.  Involvement of Oxygen‐based Radicals in Methamphetamine‐induced Neurotoxicity: Evidence from the Use of CuZnSOD Transgenic Mice a , 1994, Annals of the New York Academy of Sciences.

[18]  J. Cambier,et al.  Activation of phosphatidylinositol-3' kinase by Src-family kinase SH3 binding to the p85 subunit. , 1994, Science.

[19]  D. Sulzer,et al.  Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[20]  N. Neff,et al.  K‐252a Induces Tyrosine Phosphorylation of the Focal Adhesion Kinase and Neurite Outgrowth in Human Neuroblastoma SH‐SY5Y Cells , 1995, Journal of neurochemistry.

[21]  D. Sulzer,et al.  Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  C. Epstein,et al.  AP‐1 DNA‐binding activation by methamphetamine involves oxidative stress , 1996, Synapse.

[23]  E. Hall,et al.  Treatment of mice with methamphetamine produces cell loss in the substantia nigra , 1996, Brain Research.

[24]  D. Sulzer,et al.  Reserpine inhibits amphetamine action in ventral midbrain culture. , 1996, Molecular pharmacology.

[25]  R. Dringen,et al.  Glutathione Content as an Indicator for the Presence of Metabolic Pathways of Amino Acids in Astroglial Cultures , 1996, Journal of neurochemistry.

[26]  J. Cadet,et al.  Methamphetamine induces apoptosis in immortalized neural cells: Protection by the Proto‐Oncogene, bcl‐2 , 1997, Synapse.

[27]  G. Kroemer,et al.  The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death , 1997, Oncogene.

[28]  Y. Yamaoka,et al.  Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c. , 1998, Journal of immunology.

[29]  N. Neff,et al.  Motoneuron Apoptosis Is Blocked by CEP-1347 (KT 7515), a Novel Inhibitor of the JNK Signaling Pathway , 1998, The Journal of Neuroscience.

[30]  N. Neff,et al.  CEP‐1347/KT7515, a JNK pathway inhibitor, supports the in vitro survival of chick embryonic neurons , 1998, Neuroreport.

[31]  D. Sengelaub,et al.  CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivo. , 1998, Journal of neurobiology.

[32]  N. Neff,et al.  Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis , 1998, Neuroscience.

[33]  S. Kish,et al.  Rat striatal levels of the antioxidant glutathione are decreased following binge administration of methamphetamine , 1998, Neuroscience Letters.

[34]  M. Miller,et al.  CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. , 1999, The Journal of pharmacology and experimental therapeutics.

[35]  N. Neff,et al.  CEP‐1347 (KT7515), an Inhibitor of JNK Activation, Rescues Sympathetic Neurons and Neuronally Differentiated PC12 Cells from Death Evoked by three Distinct Insults , 1999, Journal of neurochemistry.

[36]  R. Scott,et al.  MPTP Activates c‐Jun NH2‐Terminal Kinase (JNK) and Its Upstream Regulatory Kinase MKK4 in Nigrostriatal Neurons In Vivo , 2000, Journal of neurochemistry.

[37]  K. O’Malley,et al.  The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation , 2000, The Journal of Biological Chemistry.

[38]  L. Greene,et al.  CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family* , 2001, The Journal of Biological Chemistry.

[39]  D. Bozyczko‐Coyne,et al.  CEP‐1347/KT‐7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Aβ‐induced cortical neuron apoptosis , 2001, Journal of neurochemistry.

[40]  L. Greene,et al.  β‐Amyloid‐induced neuronal apoptosis requires c‐Jun N‐terminal kinase activation , 2001, Journal of neurochemistry.

[41]  K. O’Malley,et al.  Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity. , 2001, Annals of neurology.

[42]  M. Leist,et al.  In vivo and in vitro evidence for extracellular caspase activity released from apoptotic cells. , 2001, Biochemical and biophysical research communications.

[43]  David Blum,et al.  Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.

[44]  J. Uney,et al.  Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  β‐Amyloid‐induced neuronal apoptosis requires c‐Jun N‐terminal kinase activation , 2001, Journal of neurochemistry.

[46]  G. Hanson,et al.  A single methamphetamine administration rapidly decreases vesicular dopamine uptake. , 2002, The Journal of pharmacology and experimental therapeutics.

[47]  D. Sulzer,et al.  The neuromelanin of human substantia nigra and its interaction with metals , 2002, Journal of Neural Transmission.

[48]  P. Brundin,et al.  Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line* , 2002, The Journal of Biological Chemistry.

[49]  A. Lin,et al.  The true face of JNK activation in apoptosis , 2002, Aging cell.

[50]  J. Cadet,et al.  Mice with partial deficiency of c-Jun show attenuation of methamphetamine-induced neuronal apoptosis. , 2002, Molecular pharmacology.

[51]  S. Gammeltoft,et al.  Activation of the c‐Jun N Terminal Kinase Pathway in an Animal Model of Parkinson's Disease , 2002, Annals of the New York Academy of Sciences.

[52]  Charles A. Harris,et al.  Inhibition of the c-Jun N-Terminal Kinase Signaling Pathway by the Mixed Lineage Kinase Inhibitor CEP-1347 (KT7515) Preserves Metabolism and Growth of Trophic Factor-Deprived Neurons , 2002, The Journal of Neuroscience.

[53]  D. Sulzer,et al.  Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis , 2002, The Journal of Neuroscience.

[54]  J. Yabut,et al.  Glutathione depletion and oxidative stress. , 2002, Parkinsonism & related disorders.

[55]  Philippe P Roux,et al.  K252a and CEP1347 Are Neuroprotective Compounds That Inhibit Mixed-lineage Kinase-3 and Induce Activation of Akt and ERK* , 2002, The Journal of Biological Chemistry.

[56]  Patrik Brundin,et al.  Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.

[57]  N. Barmack,et al.  Vestibularly Evoked Climbing‐Fiber Responses Modulate Simple Spikes in Rabbit Cerebellar Purkinje Neurons , 2002, Annals of the New York Academy of Sciences.

[58]  A. Maroney,et al.  Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. , 2002, Progress in medicinal chemistry.

[59]  S. Chung,et al.  Methamphetamine-induced apoptosis in a CNS-derived catecholaminergic cell line. , 2002, Molecules and cells.

[60]  J. Cadet,et al.  Methamphetamine causes coordinate regulation of Src, Cas, Crk, and the Jun N-terminal kinase-Jun pathway. , 2002, Molecular pharmacology.

[61]  J. Hirrlinger,et al.  Glutathione Pathways in the Brain , 2003, Biological chemistry.

[62]  R. Paules,et al.  An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. , 2003, Molecular cell.

[63]  J. Andersen,et al.  The Role of c‐Jun N‐Terminal Kinase (JNK) in Parkinson's Disease , 2003, IUBMB life.

[64]  D. Sulzer,et al.  Intracellular Patch Electrochemistry: Regulation of Cytosolic Catecholamines in Chromaffin Cells , 2003, The Journal of Neuroscience.

[65]  Pasko Rakic,et al.  JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Jeppe Falsig,et al.  Specific Modulation of Astrocyte Inflammation by Inhibition of Mixed Lineage Kinases with CEP-13471 , 2004, The Journal of Immunology.

[67]  Eugene M. Johnson,et al.  Mixed-lineage kinases: a target for the prevention of neurodegeneration. , 2004, Annual review of pharmacology and toxicology.

[68]  Ming-tao Li,et al.  SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson’s disease , 2004, Neuroscience Research.

[69]  M. Leist,et al.  Improvement of embryonic dopaminergic neurone survival in culture and after grafting into the striatum of hemiparkinsonian rats by CEP‐1347 , 2003, Journal of neurochemistry.

[70]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.